(Reuters) -The U.S. Meals and Drug Administration has accepted Elanco Animal Well being (NYSE:)’s pores and skin illness therapy for canines, the well being regulator’s web site confirmed on Thursday.

The oral drug, Zenrelia, is to manage pruritus, or itching, related to allergic dermatitis and management of atopic dermatitis in canines a minimum of 12 months of age.

Zenrelia, an immunosuppressant,is run as soon as every day, with or with out meals.

Shares of the corporate rose 3% in afternoon commerce.

The corporate didn’t instantly reply to Reuters’ request for pricing and availability.

The label of the drug recommends it ought to have a 28-day to 3-month washout interval earlier than any vaccination, and shouldn’t be administered for a minimum of 28 days afterwards.

Zenrelia belongs to a category of medicine often known as JAK inhibitors, which block inflammation-causing enzymes often known as Janus kinases.